High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

• Published in: PloS one Vol. 13; no. 4; p. e0195068
• Main Authors: Pasquau, Juan, Hidalgo-Tenorio, Carmen, Montes, María Luisa, Romero-Palacios, Alberto, Vergas, Jorge, Sanjoaquín, Isabel, Hernández-Quero, José, Aguirrebengoa, Koldo, Orihuela, Francisco, Imaz, Arkaitz, Ríos-Villegas, María José, Flores, Juan, Fariñas, María Carmen, Vázquez, Pilar, Galindo, María José, García-Mercé, Isabel, Lozano, Fernando, de Los Santos, Ignacio, de Jesus, Samantha Elizabeth, García-Vallecillos, Coral
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12.04.2018; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Antiretroviral agents; Antiretroviral drugs; Antiviral drugs; Biology and Life Sciences; CD4 antigen; Clinical trials; Dosage and administration; Drug therapy; Effectiveness; Health aspects; HIV; HIV infections; HIV patients; Human immunodeficiency virus; Immunology; Incidence; Lopinavir; Medical diagnosis; Medicine and Health Sciences; Mutation; Patient outcomes; Patients; Protease inhibitors; Proteinase inhibitors; Quality of life; Research and Analysis Methods; Ribonucleic acid; Ritonavir; RNA; Safety; Safety and security measures; Statistical analysis; Switching; Therapy; Treatment outcome; Spain
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0195068

The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral triple treatment with a boosted protease inhibitor (TT). This was a 24-week, open-label, multicentre study in virologically-suppressed HIV-infected participants (N = 225) with a 2:1 randomization: 146 patients who switched to MT were compared with 79 patients who remained on a TT regimen. The primary endpoint was change in patient-reported outcomes in quality of life as measured by the MOS-HIV and EQ-5D questionnaires. Secondary endpoints included treatment adherence, patient satisfaction, incidence of adverse events and differences in plasma HIV-1 RNA viral load (VL) and CD4 cell counts. Baseline quality of life, measured with the MOS-HIV score, was very good (overall score of 83 ± 10.5 in the MT arm and 82.3 ± 11.3 in the TT arm) and suffered no change during the study in any of the arms (at week 24, 83.5 ± 12.2 in MT arm and 81.9 ± 12.7 in TT arm), without statistically significant differences when compared. In regards to adherence to therapy and patient satisfaction, some aspects (number of doses forgotten in the last week and satisfaction of treatment measured with the CESTA score, dimension 1) improved significantly with MT. There were also no differences in the incidence and severity of adverse events, even though 22.8% of those in the MT arm switched their treatment when they were included in the study. Moreover, there was also no significant difference between the immunological and virological evolution of MT and TT. In the MT arm, the VL was always undetectable in 83% of patients (vs 90.7% in the TT arm) and there were only 6.7% of virological failures with VL > 50 copies/mL (vs 2.3% in the TT arm), without resistance mutations and with resuppression of VL after switching back to TT. In a new clinical trial, monotherapy as a treatment simplification strategy in HIV-1 infected patients with sustained viral suppression has demonstrated quality of life, safety and efficacy profiles comparable to those of conventional triple therapy regimens.